相关实验视频
Updated: May 15, 2025

Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
在接受免疫化疗的扩散型大B细胞淋巴瘤患者中,严重感染的发生率和危险因素
Haiqiu Zhao1, Rong Su1, Jie Luo2
1Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, 1 Youyi Road, Chongqing, 400042, China.
严重的感染是常见的扩散型大B细胞淋巴瘤 (DLBCL) 患者治疗与rituximab化疗 (R-C). 晚期疾病,吸烟,自身免疫疾病和较高的德克萨米他剂量会增加风险,而G-CSF可能会降低风险.
科学领域:
- 在瘤学瘤学.
- 传染性疾病 传染性疾病
- 临床研究 临床研究
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种侵略性的非霍奇金淋巴瘤.
- 里图西马布化疗 (R-C) 是DLBCL的标准治疗方法.
- 感染是DLBCL患者接受R-C的发病率和死亡率的重要原因.
研究的目的:
- 确定在接受R-C.的DLBCL患者中严重感染 (SI) 的发生率.
- 确定与该患者群体中SI发展相关的独立风险因素.
主要方法:
- 对300名新诊断的DLBCL患者进行了回顾性研究,这些患者接受了R-C治疗.
- SI定义为需要住院治疗的感染;不包括COVID-19.
- 多变量物流回归分析以确定SI的独立风险因素.
主要成果:
- 39.0%的患者发生SI,其中86.3%发生在治疗六个月内.
- 对SI的独立风险因素包括晚期疾病,吸烟史,自身免疫性疾病和较高的德克萨米他剂量 (≥15 mg/d).
- 预防性颗粒细胞刺激因子 (G-CSF) 的使用与SI的风险降低有关.
结论:
- 感染是DLBCL患者接受R-C治疗的常见并发症.
- 识别独立的风险因素可以制定有针对性的预防策略.
- 这些发现可以帮助临床医生制定个性化计划,以减轻感染风险.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
相关概念视频
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...